Strengthening Families & Communities LLC Acquires 13,086 Shares of Becton, Dickinson and Company $BDX

Strengthening Families & Communities LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 1,130.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,244 shares of the medical instruments supplier’s stock after purchasing an additional 13,086 shares during the quarter. Strengthening Families & Communities LLC’s holdings in Becton, Dickinson and Company were worth $2,730,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. Empowered Funds LLC increased its holdings in Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after purchasing an additional 1,354 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Becton, Dickinson and Company by 5.1% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,639 shares of the medical instruments supplier’s stock worth $6,311,000 after purchasing an additional 1,792 shares in the last quarter. Ameritas Advisory Services LLC acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $40,000. Finally, Ascent Group LLC lifted its holdings in shares of Becton, Dickinson and Company by 23.5% in the second quarter. Ascent Group LLC now owns 3,686 shares of the medical instruments supplier’s stock valued at $635,000 after purchasing an additional 702 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on BDX shares. Piper Sandler increased their price objective on Becton, Dickinson and Company from $190.00 to $205.00 and gave the stock a “neutral” rating in a report on Wednesday, January 28th. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Jefferies Financial Group boosted their price objective on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Finally, Stifel Nicolaus lifted their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Four research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $209.00.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $202.29 on Tuesday. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The company’s fifty day simple moving average is $198.76 and its 200 day simple moving average is $191.57. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99. The company has a market cap of $57.63 billion, a price-to-earnings ratio of 34.70, a PEG ratio of 2.25 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.92 by $0.04. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The company had revenue of $5.89 billion for the quarter, compared to analyst estimates of $5.91 billion. During the same period in the previous year, the business earned $3.81 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company’s payout ratio is presently 72.04%.

Becton, Dickinson and Company declared that its Board of Directors has authorized a share buyback program on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 2,680 shares of company stock worth $539,848. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.